Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15581870 | 0.93 | PKM (0.48) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL23246690 | 0.93 | PKM (0.43) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL5895758 | 0.88 | USP2 (0.41) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL29381025 | 0.87 | PKM (0.39) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL5895665 | 0.86 | PKM (0.34) | PKMCYP4F2CYP4A11 | |
| SCHEMBL23246952 | 0.86 | CYP4F2 (0.47) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL2799709 | 0.85 | PKM (0.47) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL16101043 | 0.84 | PKM (0.46) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL23247143 | 0.83 | CYP4F2 (0.36) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL15076439 | 0.83 | USP2 (0.41) | PKMUSP2SMN1; SMN2RECQLHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021249913-A9 | 2'-(QUINOLIN-3-YL)-5',6'-DIHYDROSPIRO[AZETIDINE-3,4'-PYRROLO[1,2-B]PYRAZOLE]-1-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS MAP4K1 (HPK1) INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-03 | — | — | WO | disclosed |
| US-7091211-B2 | Cyclopentyl modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR5, CXCR1, ACKR3 | PKM 2841/4885USP2 4590/4885SMN1; SMN2 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.